Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Moran Wealth Management LLC

Moran Wealth Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 76.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,590 shares of the biopharmaceutical company’s stock after selling 15,211 shares during the period. Moran Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $2,410,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after buying an additional 2,501 shares during the period. Sepio Capital LP grew its stake in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 842 shares in the last quarter. Founders Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after acquiring an additional 538 shares in the last quarter. PGGM Investments increased its position in shares of Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent analyst reports. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Sanford C. Bernstein lifted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $576.42 on Thursday. The company has a market cap of $61.09 billion, a PE ratio of 14.53, a P/E/G ratio of 1.84 and a beta of 0.31. The company has a fifty day moving average price of $574.15 and a two-hundred day moving average price of $563.61. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,020.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the prior year, the company earned $11.56 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.